Fairvalue-Calculator Fairvalue-Calculator
EN DE

Corline Biomedical AB (CLBIO) Fair Value & Analysis

Healthcare · SE · Market cap 470M SEK

Pricekr 17.60
Fair Valuekr 16.14
Upside-8.3%
Quality95/100
Evidence: Low Range kr 12.11 – kr 20.18

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Corline Biomedical AB (CLBIO) currently trades at kr 17.60, while our model-based Fair Value estimate is kr 16.14 — implying the stock looks roughly 8.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company also provides medical devices, such as coated stents and coated ablation catheter. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Corline Biomedical AB (CLBIO) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 16.14 versus a price of kr 17.60 — about −8% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CLBIO?
Our 21-model fair value for Corline Biomedical AB is kr 16.14 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 17.60.
What is the quality score of CLBIO?
Corline Biomedical AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.